Trevi Therapeutics TRVI 深 沪
已收盘 12-19 16:00:00 美东时间
13.015
+0.825
+6.77%
华盛通- 最 高14.39
- 今 开12.48
- 成交量 166.10万股
- 最 低 11.21
- 昨 收 12.19
- 总市值 5.03亿
- 52周最高 14.39
- 市盈率 静 --
- 换手率 4.29%
- 52周最低 3.4715
- 委 比 21.22%
- 总股本 3868.56万
- 历史最高 14.39
- 量 比 0.91
- 振 幅 26.09%
- 历史最低 0.46
- 每 手 1
- 风险率 2.57%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Earnings Scheduled For November 13, 2025
Companies Reporting Before The Bell • Edgewell Personal Care (NYSE:EPC) is proj...
11-13 19:11
Market-Moving News for March 10th
RKT: -10% | Rocket Companies shares are trading lower after the company announced it will acquire Redfin in an all-stock transaction valued at $12.50 per share. MLYS: 34% | Mineralys Therapeutics shares
03-10 19:29
Why Checkpoint Therapeutics Shares Are Trading Higher By Around 66%; Here Are 20 Stocks Moving Premarket
Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) rose sharply in today's p...
03-10 18:44
伊芙美尔医疗盘中异动 下午盘股价大涨7.08%
北京时间2024年12月13日03时47分，伊芙美尔医疗（ICCC.us）股票出现波动，股价急速拉升7.08%。截至发稿，该股报4.84美元/股，成交量2423股，换手率0.03%，振幅0.00%。 最近的财报数据显示，该股实现营业收入6.01百万美元，净利润-701690.00美元，每股收益-0.09美元，毛利1.58百万美元，市盈率-9.39倍。 机构评级方面，目前暂无机构对该股做出“买入、持有、卖出”建议。 伊芙美尔医疗股票所在的生物技术行业中，整体跌幅为1.32%。其相关个股中，Cero Therapeutics Holdings Inc C/Wts 13/02/2029 (To Pu...
2024-12-13 03:47
EF Hutton Maintains Buy on Trevi Therapeutics, Maintains $21 Price Target
EF Hutton analyst Jason Kolbert maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and maintains $21 price target.
2024-09-17 22:33
Trevi Therapeutics To Present Data From Ph2a CANAL Trial At The ERS Congress 2024
Professor Jacky Smith will present on the correlation between the change in objective cough count and improvement in patient-reported outcomes with nalbuphine ER in IPF patients NEW HAVEN, Conn., Sept. 4, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutica...
2024-09-05 04:15
Raymond James Starts Trevi Therapeutics With Outperform Rating
06:26 AM EDT, 08/30/2024 (MT Newswires) -- Trevi Therapeutics (TRVI) has average rating of buy and price targets ranging from $6 to $21, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia...
2024-08-30 18:26
HC Wainwright Initiates Trevi Therapeutics at Buy
06:15 AM EDT, 08/30/2024 (MT Newswires) -- Trevi Therapeutics (TRVI) has average rating of buy and price targets ranging from $6 to $21, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia...
2024-08-30 18:15
